Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis

C. Y. Chiang, A. Van Deun, H. L. Rieder

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The 9-month regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) piloted in Bangladesh and used, with modifications, in Cameroon and Niger, has achieved treatment success in a very large proportion of patients; gatifloxacin (GFX) is likely to have played a critical role in this success. Two months after the publication of a study reporting that GFX and not moxifloxacin (MFX) was associated with dysglycaemia, the manufacturer announced the withdrawal of GFX from the market. The findings of that study may have less significance for the majority of MDR-TB patients living in high-incidence countries who are much younger, have a lower risk of dysglycaemia and suffer from a highly fatal condition. The problem of dysgly-caemia is not limited to GFX use and may occur with other fluoroquinolones; furthermore, GFX-associated dysglycemia was manageable among those MDR-TB patients in Bangladesh and Niger in whom it occurred. GFX has now become unavailable in Bangladesh, Cameroon, Niger and other countries piloting the shorter MDR-TB regimens, depriving resource-poor countries of an efficacious, effective and inexpensive drug with a demonstrated good safety profile for the given indication. There is little reason not to make GFX available for MDR-TB treatment as long as the superiority of non-GFX-based MDR-TB regimens is not demonstrated.

Original languageEnglish
JournalInternational Journal of Tuberculosis and Lung Disease
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Multidrug-Resistant Tuberculosis
Niger
Bangladesh
Cameroon
Therapeutics
Product Recalls and Withdrawals
Fluoroquinolones
gatifloxacin
Publications
Safety
Incidence
Pharmaceutical Preparations

Keywords

  • Dysglycaemia
  • GFX
  • Multidrug resistance
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis. / Chiang, C. Y.; Van Deun, A.; Rieder, H. L.

In: International Journal of Tuberculosis and Lung Disease, Vol. 20, No. 9, 01.09.2016.

Research output: Contribution to journalReview article

@article{349fb985e03f4e86b7758a94b9cf7d14,
title = "Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis",
abstract = "The 9-month regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) piloted in Bangladesh and used, with modifications, in Cameroon and Niger, has achieved treatment success in a very large proportion of patients; gatifloxacin (GFX) is likely to have played a critical role in this success. Two months after the publication of a study reporting that GFX and not moxifloxacin (MFX) was associated with dysglycaemia, the manufacturer announced the withdrawal of GFX from the market. The findings of that study may have less significance for the majority of MDR-TB patients living in high-incidence countries who are much younger, have a lower risk of dysglycaemia and suffer from a highly fatal condition. The problem of dysgly-caemia is not limited to GFX use and may occur with other fluoroquinolones; furthermore, GFX-associated dysglycemia was manageable among those MDR-TB patients in Bangladesh and Niger in whom it occurred. GFX has now become unavailable in Bangladesh, Cameroon, Niger and other countries piloting the shorter MDR-TB regimens, depriving resource-poor countries of an efficacious, effective and inexpensive drug with a demonstrated good safety profile for the given indication. There is little reason not to make GFX available for MDR-TB treatment as long as the superiority of non-GFX-based MDR-TB regimens is not demonstrated.",
keywords = "Dysglycaemia, GFX, Multidrug resistance, Tuberculosis",
author = "Chiang, {C. Y.} and {Van Deun}, A. and Rieder, {H. L.}",
year = "2016",
month = "9",
day = "1",
doi = "10.5588/ijtld.15.0884",
language = "English",
volume = "20",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "9",

}

TY - JOUR

T1 - Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis

AU - Chiang, C. Y.

AU - Van Deun, A.

AU - Rieder, H. L.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The 9-month regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) piloted in Bangladesh and used, with modifications, in Cameroon and Niger, has achieved treatment success in a very large proportion of patients; gatifloxacin (GFX) is likely to have played a critical role in this success. Two months after the publication of a study reporting that GFX and not moxifloxacin (MFX) was associated with dysglycaemia, the manufacturer announced the withdrawal of GFX from the market. The findings of that study may have less significance for the majority of MDR-TB patients living in high-incidence countries who are much younger, have a lower risk of dysglycaemia and suffer from a highly fatal condition. The problem of dysgly-caemia is not limited to GFX use and may occur with other fluoroquinolones; furthermore, GFX-associated dysglycemia was manageable among those MDR-TB patients in Bangladesh and Niger in whom it occurred. GFX has now become unavailable in Bangladesh, Cameroon, Niger and other countries piloting the shorter MDR-TB regimens, depriving resource-poor countries of an efficacious, effective and inexpensive drug with a demonstrated good safety profile for the given indication. There is little reason not to make GFX available for MDR-TB treatment as long as the superiority of non-GFX-based MDR-TB regimens is not demonstrated.

AB - The 9-month regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) piloted in Bangladesh and used, with modifications, in Cameroon and Niger, has achieved treatment success in a very large proportion of patients; gatifloxacin (GFX) is likely to have played a critical role in this success. Two months after the publication of a study reporting that GFX and not moxifloxacin (MFX) was associated with dysglycaemia, the manufacturer announced the withdrawal of GFX from the market. The findings of that study may have less significance for the majority of MDR-TB patients living in high-incidence countries who are much younger, have a lower risk of dysglycaemia and suffer from a highly fatal condition. The problem of dysgly-caemia is not limited to GFX use and may occur with other fluoroquinolones; furthermore, GFX-associated dysglycemia was manageable among those MDR-TB patients in Bangladesh and Niger in whom it occurred. GFX has now become unavailable in Bangladesh, Cameroon, Niger and other countries piloting the shorter MDR-TB regimens, depriving resource-poor countries of an efficacious, effective and inexpensive drug with a demonstrated good safety profile for the given indication. There is little reason not to make GFX available for MDR-TB treatment as long as the superiority of non-GFX-based MDR-TB regimens is not demonstrated.

KW - Dysglycaemia

KW - GFX

KW - Multidrug resistance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84982166084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982166084&partnerID=8YFLogxK

U2 - 10.5588/ijtld.15.0884

DO - 10.5588/ijtld.15.0884

M3 - Review article

C2 - 27510237

AN - SCOPUS:84982166084

VL - 20

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 9

ER -